The Europe Viral Vector Production Market would witness market growth of 18.9% CAGR during the forecast period (2023-2030).
The increase in demand for gene therapy and the growth in awareness about its potential benefits among healthcare professionals and patients have also fueled the expansion of the viral vector production market. There is greater recognition of the crucial role of viral vectors in delivering therapeutic genes. This increased demand and awareness have driven investments in viral vector production and propelled market growth. On the other hand, the high cost of production and stringent regulatory requirements pose significant challenges to the growth of the viral vector production market.
Furthermore, the complex and intricate manufacturing processes in producing viral vectors can be costly, requiring specialized facilities, equipment, and skilled personnel. In addition, stringent regulatory frameworks, including Good Manufacturing Practices (GMP), are in place to ensure viral vectors' safety, efficacy, and quality. The cost and regulatory hurdles create barriers to market entry, particularly for smaller companies, and can impede the overall growth and scalability of the market.
Europe has witnessed a growing pipeline of gene therapies targeting various diseases, including rare genetic disorders, cancers, and neurodegenerative conditions. European companies quickly adopt advanced technologies in bioprocessing, automation, and analytical tools. These technological advancements enhance the efficiency and quality of viral vector production processes. Due to the aforementioned factors the market growth will drive in this region.
The Germany market dominated the Europe Viral Vector Production Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $224.1 Million by 2030. The UK market is exhibiting a CAGR of 17.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 19.8% during (2023 - 2030).
Based on Type, the market is segmented into Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others. Based on Indication, the market is segmented into Cancer, Genetic Disorders, Infectious Diseases, and Others. Based on Application, the market is segmented into Gene Therapy, and Vaccinology. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The increase in demand for gene therapy and the growth in awareness about its potential benefits among healthcare professionals and patients have also fueled the expansion of the viral vector production market. There is greater recognition of the crucial role of viral vectors in delivering therapeutic genes. This increased demand and awareness have driven investments in viral vector production and propelled market growth. On the other hand, the high cost of production and stringent regulatory requirements pose significant challenges to the growth of the viral vector production market.
Furthermore, the complex and intricate manufacturing processes in producing viral vectors can be costly, requiring specialized facilities, equipment, and skilled personnel. In addition, stringent regulatory frameworks, including Good Manufacturing Practices (GMP), are in place to ensure viral vectors' safety, efficacy, and quality. The cost and regulatory hurdles create barriers to market entry, particularly for smaller companies, and can impede the overall growth and scalability of the market.
Europe has witnessed a growing pipeline of gene therapies targeting various diseases, including rare genetic disorders, cancers, and neurodegenerative conditions. European companies quickly adopt advanced technologies in bioprocessing, automation, and analytical tools. These technological advancements enhance the efficiency and quality of viral vector production processes. Due to the aforementioned factors the market growth will drive in this region.
The Germany market dominated the Europe Viral Vector Production Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $224.1 Million by 2030. The UK market is exhibiting a CAGR of 17.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 19.8% during (2023 - 2030).
Based on Type, the market is segmented into Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others. Based on Indication, the market is segmented into Cancer, Genetic Disorders, Infectious Diseases, and Others. Based on Application, the market is segmented into Gene Therapy, and Vaccinology. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Andelyn Biosciences, Inc.
- Charles River Laboratories International, Inc.
- Danaher Corporation
- FinVector Oy (Ferring Ventures S/A)
- Thermo Fisher Scientific, Inc.
- Novartis AG
- Takara Bio Inc. (Takara Holdings Inc.)
- Avid Bioservices, Inc.
- Oxford Biomedica plc
- Lonza Group Ltd.
Market Report Segmentation
By Type- Adeno-Associated Viral Vectors
- Lentiviral Vectors
- Adenoviral Vectors
- Retroviral Vectors
- Others
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
- Gene Therapy
- Vaccinology
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Europe Viral Vector Production Market, by Type
Chapter 6. Europe Viral Vector Production Market, by Indication
Chapter 7. Europe Viral Vector Production Market, by Application
Chapter 8. Europe Viral Vector Production Market, by Country
Chapter 9. Company Profiles
Companies Mentioned
- Andelyn Biosciences, Inc.
- Charles River Laboratories International, Inc.
- Danaher Corporation
- FinVector Oy (Ferring Ventures S/A)
- Thermo Fisher Scientific, Inc.
- Novartis AG
- Takara Bio Inc. (Takara Holdings Inc.)
- Avid Bioservices, Inc.
- Oxford Biomedica plc
- Lonza Group Ltd.
Methodology
LOADING...
